稳心颗粒治疗窦性心动过缓合并室性早搏的临床观察  

Wenxinkeli treatment of sinus bradycardia associated with the clinical observation of premature ventricular contractions

作　　者：孙桂玲[1] 

机构地区：[1]山东省临沂市人民医院,276000

出　　处：《中国现代药物应用》2012年第11期21-22,共2页Chinese Journal of Modern Drug Application

摘　　要：目的观察稳心颗粒治疗窦性心动过缓合并室性早搏的疗效与安全性。方法选择窦性心动过缓合并室性早搏患者60例,给予稳心颗粒9g/次,3次/d口服,4周后复查心电图1次及24h动态心电图(Holter)。观察治疗前后室早次数、心率、临床症状改善情况及药物不良反应情况。结果治疗后临床症状明显改善、早搏明显减少。结论稳心颗粒治疗窦性心动过缓合并室性早搏安全有效且无明显不良反应。Objective Observed Wenxinkeli the treatment of sinus bradycardia associated with prema- ture ventricular contractions of the efficacy and security. Methods 60 cases of premature ventricular contrac- tions in patients with sinus bradycardia merge to give 9 g / Wenxinkeli, 3 times / day orally, four weeks after the review of the ECG and 24 hour ambulatory ECG （Hoher）. Observation and treatment before and after ven- tricular premature frequency, heart rate, symptom improvement and adverse drug reactions. Results After treatment, clinical symptoms improved significantly, significantly reduced premature. Conclusion The safe and effective Wenxinkeli the treatment of sinus bradycardia associated with premature ventricular contractions and no significant adverse reactions.

关 键 词：稳心颗粒 窦性心动过缓合并室性早搏 

分 类 号：R259[医药卫生—中西医结合]